Tetsuzo Tauchi

Summary

Affiliation: Tokyo Medical University
Country: Japan

Publications

  1. Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, et al. Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib. Int J Mol Sci. 2016;17:570 pubmed publisher
    ..Our study suggests a possible role of miR-215 in successful IM discontinuation. ..
  2. request reprint
    Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res. 2003;9:4267-73 pubmed
    ....
  3. request reprint
    Tauchi T, Yoshimura A, Ohyashiki K. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway. Exp Hematol. 2001;29:356-61 pubmed
    ..The results suggest that CIS1 is an endogenous inhibitor of p210 BCR/ABL and is likely to be important in the pathogenesis of Ph-positive leukemia. ..

Locale

Detail Information

Publications3

  1. Ohyashiki K, Umezu T, Katagiri S, Kobayashi C, Azuma K, Tauchi T, et al. Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib. Int J Mol Sci. 2016;17:570 pubmed publisher
    ..Our study suggests a possible role of miR-215 in successful IM discontinuation. ..
  2. request reprint
    Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res. 2003;9:4267-73 pubmed
    ....
  3. request reprint
    Tauchi T, Yoshimura A, Ohyashiki K. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway. Exp Hematol. 2001;29:356-61 pubmed
    ..The results suggest that CIS1 is an endogenous inhibitor of p210 BCR/ABL and is likely to be important in the pathogenesis of Ph-positive leukemia. ..